Updated version 1 - According to Bloomberg, Oracle invoked the "force majeure" clause to mitigate risks in its data center project.
路透社2026/09/24 13:06Details supplemented in paragraphs 3 and 4
Reuters, September 24 - According to a Thursday report by Bloomberg, Oracle (ORCL.N) is seeking to avoid the risk of rising costs from a major data center project in New Mexico by issuing a "force majeure" notice to developer Blue Owl (OWL.N).
The report, citing people familiar with the matter, said that after the news broke, the company's shares fell about 4% in pre-market trading. Reuters was unable to independently verify the information.
According to the report, Oracle aims to delay payments to deal with potential setbacks to the data center project known as "Project Jupiter" if it fails to become operational as scheduled in 2028, rather than withdrawing as the main tenant.
When uncontrollable issues arise, companies usually invoke force majeure clauses to be exempted from contractual obligations. Oracle and Blue Owl have not yet responded to Reuters' requests for comment.
(To assist non-native English speakers, Reuters provides automated translations of its reports into several other languages. Because automated translation may contain errors or fail to capture the desired context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for reader convenience. Reuters accepts no responsibility for any damage or loss arising from use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Swiss Franc weakens as US Dollar (USD) gains on escalating geopolitical conflicts
Swiss Franc: Range-bound within 0.8245–0.8365 band against US Dollar – UOB
BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released
October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)
Crypto prices
More
